Clinical trial

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-08-01

PhasePHASE4

Study timeline

Study start (actual)2014-08-01Date precision: month

Registry last updated2018-06-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rhematoid Arthritisunresolved

Interventions

Tofacitinib with methotrexateDRUG

Tofacitinib without methotrexateDRUG

Adalimumab with methotrexateBIOLOGICAL

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

BucharestRomania5 Los AngelesCalifornia, United States4 HoustonTexas, United States3 BangkokThailand3 LimaPeru3 DallasTexas, United States2 San AntonioTexas, United States2 SeoulSouth Korea2 MoscowRussia2 WarsawPoland2 SofiaBulgaria2 HaifaIsrael2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02187055 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.